Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Rethinking clinical delivery of adult stem cell therapies

Nature Biotechnology volume 32, pages 729–735 (2014)Cite this article

Subjects

A transformation needs to take place in the way we manufacture and deliver adult stem cell therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Key processes of a centralized production of autologous stem cell therapy using a cGMP facility with manual operation of culture processes.
Figure 2: Key processes of the decentralized production of a generalized autologous stem cell therapy using a fully automated benchtop culture system in the patient's primary care facility.

References

  1. Abdallah, B.M. & Kassem, M. Gene Ther. 15, 109–116 (2008).

    Article  CAS  Google Scholar 

  2. Glotzbach, J.P. Curr. Probl. Surg. 48, 148–212 (2011).

    Article  Google Scholar 

  3. Thomas, R. & Williams, D.J. Pharmatech 33, 74–79 (2009).

    Google Scholar 

  4. Halme, D.G. & Kessler, D. N. Engl. J. Med. 355, 1730–1735 (2006).

    Article  CAS  Google Scholar 

  5. Huang, X.-P. et al. Circulation 122, 2419–2429 (2010).

    Article  CAS  Google Scholar 

  6. Atoui, R. & Chiu, R. Stem Cells Trans. Med. 1, 200–205 (2012).

    Article  CAS  Google Scholar 

  7. Porter, D.L. Hematology (Am. Soc. Hematol. Educ. Program) 2011, 292–298 (2011).

    Article  Google Scholar 

  8. Hakimian, R. & Korn, D. J. Am. Med. Assoc. 292, 2500–2505 (2004).

    Article  CAS  Google Scholar 

  9. Freeman, M. & Fuerst, M. J. Transl. Med. 10, 60 (2012).

    Article  Google Scholar 

  10. Cosh, E., Girling, A., Lilford, R., McAteer, H. & Young, T. J. Commerc. Biotechnol. 13, 263–271 (2007).

    Article  Google Scholar 

  11. O'Brien, J. Fortune http://fortune.com/2012/09/28/the-great-stem-cell-dilemma/ (8 October 2012).

    Google Scholar 

  12. Anonymous. Inbound Logistics 30, 75–76 (2010) http://www.inboundlogistics.com/cms/article/just-chill-moving-live-tissue/.

  13. Denault, J., Coquet, A. & Dodelet, V. BioProcess Int. 6, 14–23 (2008).

    Google Scholar 

  14. Martin, I., Smith, T. & Wendt, D. Trends Biotechnol. 27, 495–502 (2009).

    Article  CAS  Google Scholar 

  15. Santoro, R. et al. Biomaterials 31, 8946–8952 (2010).

    Article  CAS  Google Scholar 

  16. US Food and Drug Administration. Guidance for Industry: Cell selection devices for point of care production of minimally manipulated autologous peripheral blood stem cells (PBSCs) http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0290-gdl0001.pdf (US Department of Health and Human Services, 2007).

Download references

Acknowledgements

We would like to acknowledge the support of Health Technology Exchange (HTX), National Science and Engineering Research Council (NSERC) and Ontario Centres of Excellence (OCE).

Author information

Authors and Affiliations

  1. Nuala Trainor, Alexis Pietak & Tim Smith are at Octane Biotech Inc., Kingston, Ontario, Canada.,

    Nuala Trainor, Alexis Pietak & Tim Smith

Authors
  1. Nuala Trainor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexis Pietak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tim Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nuala Trainor.

Ethics declarations

Competing interests

The authors work for Octane Biotech Inc., a company that develops and manufactures bioreactor automation systems for clinical applications.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trainor, N., Pietak, A. & Smith, T. Rethinking clinical delivery of adult stem cell therapies. Nat Biotechnol 32, 729–735 (2014). https://doi.org/10.1038/nbt.2970

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2970

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing